First paper of 2026! We started with 4 genetic variants from GWAS and ended with a potential lncRNA therapeutic for ER+ breast cancer. Spent hours with co-senior author @stacedw.bsky.social bouncing ideas around, discussing results and potential mechanisms. Loved every minute! rdcu.be/eXVnl
rdcu.be
BRRIAR lncRNA alters breast cancer risk by modulating interferon signaling in cis and in trans